More News

Technological Advances in Perimetry Market Will Drive 2 Percent Growth

Perimetry devices continue to evolve, as the technology advances toward making visual field testing faster, more flexible, more accurate, and less expensive. Virtual reality headsets that boast vis...

Emerging Companies Pursuing Ophthalmic Indications, June 2022

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease. Company Location About Perceive Biotherapeutics South San Francisco, California The company ...

Rudacure Leads Latest Ophthalmic Fundraising with $16.5M Series A Round

South Korean company Rudacure led recent fundraising efforts by ophthalmic companies with a $16.5 million Series A round to advance candidates for retinal disease and dry eye. Funding for the past ...

Weekly Ophthalmic Surgeon Poll for June 2022

June 2022 Ophthalmic News Briefs

Lansheng to Commercialize SING IMT in China Samsara Vision of Far Hills, New Jersey, reported June 8 that it will collaborate with Lansheng Medical to commercialize the SING IMT in mainland China, ...

Nacuity Closes $16.5 Million Series B Financing

Nacuity Pharmaceuticals of Fort Worth, Texas, reported June 15 that it had closed a $16.5 million Series B financing to continue advancing ophthalmic treatments designed to combat oxidative stress....

Bausch + Lomb Reports Q1-2022 Revenue of $889 Million

Bausch + Lomb reported June 8 that its Q1-2022 revenue was $889 million, a 1 percent increase over $881 million in Q1-2021. Vision Care segment revenue in Q1-2022 was $560 million, a 1 percent incr...

Iridex Gains Clearance in China for Cyclo G6 Glaucoma Platform

Laser company Iridex announced June 14 that it had gained regulatory clearance in China for its Cyclo G6 glaucoma platform. The Mountain View, California, company said the Cyclo G6 and related prob...

Nanodropper Reports High Demand for Eye Drop Bottle Adaptor

Nanodropper, of Rochester, Minnesota, announced June 15 that it had expanded the sites using its eye drop adaptor tomore than 840 clinic locations from the 10 sites that used it in June 2021. The N...

Study of Orbis AI Screenings in Rwanda Shows Immediate Feedback Improves Diabetic Eye Care

Orbis International reported June 6 that new research demonstrated that diabetic retinopathy (DR) screenings supported by artificial intelligence (AI) enhanced patients’ speed and uptake of referra...

Gene Therapy Candidate for LHON Lacks Efficacy in Early Trial, Researchers Say

Researchers at the Bascom Palmer Eye Institute reported June 1 that a 28-patient Phase I clinical trial of a gene therapy candidate for Leber hereditary optic neuropathy (LHON) failed to improve or...

Colorado Expands Scope of Practice for Optometrists to Include Glaucoma Laser Procedures, Cross-linking

The American Optometric Association reported June 8 that Colorado had expanded the scope of practice for optometrists to include laser procedures and corneal cross-linking. Colorado Gov. Jared Poli...

Grants to Support Medical Student Research in Ocular Cancer

Research to Prevent Blindness (RPB) and Castle Biosciences have partnered to offer grants to support medical students who elect to do research on ocular cancer. Ocular cancers, such as uveal melano...

EMA Validates Marketing Application for SIFI’s Akantior for Acanthamoeba Keratitis

Italy’s SIFI announced June 7 that the European Medicines Agency (EMA) had validated its marketing authorization application for Akantior (polihexanide) for Acanthamoeba keratitis (AK), a parasitic...

Ocular Therapeutix Promotes Rabia Gurses Ozden, MD, to Chief Medical Officer

Ocular Therapeutix, maker of Dextenza, announced June 8 that Rabia Gurses Ozden, MD, had been promoted to chief medical officer from her previous role as the company’s senior vice president, clinic...

Aurion Appoints Michael Goldstein, MD, MBA, as President and Chief Medical Officer

Aurion Biotech announced June 9 that it had appointed Michael Goldstein, MD, MBA, as president and chief medical officer. Based in Seattle, Boston, and Tokyo, Aurion is a clinical-stage biotech who...

LENSAR Gains FDA Clearance of Femtosecond Technology in ALLY Femto-Phaco Platform

LENSAR announced June 13 that it had received US FDA clearance for the femtosecond technology in its ALLY Adaptive Cataract Treatment System, a femto-phaco platform designed to allow surgeons to pe...

Rayner Buys Stake in Belgium Maker of Recyclable Ophthalmic Surgical Instruments

UK-based Rayner announced June 8 that it had acquired a stake in Hasa Optix, a Belgium-based manufacturer of recyclable single-use ophthalmic surgical instruments and instrument sets. Hasa Optix, f...

Corza Medical Acquires Barron Precision Instruments

Private equity firm GTCR announced June 8 that Corza Medical, one of its portfolio companies, had acquired Barron Precision Instruments. Terms of the deal were not disclosed. Barron, founded in 194...

MacuLogix Faces Insurmountable Debt, Moves to Wind Down Operations

MacuLogix Inc., maker of the AdaptDx dark adaptation screener for age-related macular degeneration (AMD), cannot pay $23 million it owes to creditors and has filed to wind down the business, accord...

Lumibird Opens New Indian Subsidiary in Mumbai

French laser company Lumibird announced June 2 that it had launched Lumibird Medical India, a Mumbai-based subsidiary, with the intent to boost sales of its Quantel Medical and Ellex ultrasound pro...

STAAR Reaches Milestone of 2 Million Visian ICLs Sold

STAAR Surgical announced June 7 that it had sold more than 2 million Visian Implantable Collamer lenses (ICLs) globally. The company reached the 1 million milestone for the Visian, a phakic lens, i...

Zeiss Reports Milestone for Veracity Surgical Planning Software

Zeiss Medical Technology, of Dublin, California, reported June 7 that its Veracity Surgical planning software had been used to plan more than 500 thousand surgical cases. Veracity is designed to in...

US Glaucoma Atlas Looks at Treatment Opportunity by Metro Area, as Adoption of MIGS and Canal-Based Procedures Reaches 22 Percent in the US

US cataract and glaucoma surgeons have 16 surgical options in their armamentarium to treat patients with glaucoma. Market Scope expects minimally invasive glaucoma surgery (MIGS) and canal-based pr...

Oertli Rebrands Domedics as Oertli Ophthalmedic

Swiss company Oertli Instrumente reported June 1 that it had integrated ophthalmic instrument maker Domedics AG into its global brand, dubbing it Oertli Ophthalmedic Schweiz AG. Oertli acquired a m...

Neurophth Therapeutics Appoints Xiaoning Guo as Chief Medical Officer

Chinese ophthalmic gene therapy company Neurophth Therapeutics announced June 2 that it had appointed Xiaoning Guo, PhD, as chief medical officer. Guo joins Neurophth from SciClone Pharmaceuticals,...

Alimera’s Steroid Implant Gets Green Light for Phase III Trial in China in DME

Alimera Sciences announced June 8 that partner Ocumension Therapeutics had received approval from Chinese regulators to begin a Phase III clinical trial in diabetic macular edema (DME) of its 0.19 ...

Samsara Vision Partners with Lansheng Medical to Commercialize SING IMT in China

Samsara Vision of Far Hills, New Jersey, reported June 8 that it will collaborate with Lansheng Medical to commercialize the SING IMT in mainland China, Macau, and Hong Kong. Lansheng is based in C...

AffaMed Doses First Patient in US Phase I Trial of Bispecific Biologic in Wet AMD

China-based AffaMed Therapeutics reported May 30 that the first patient had been dosed in its US Phase I study of AM712, a bispecific biologic, in wet age-related macular degeneration (AMD). The mo...

Biogen and Samsung Bioepis’ Ranibizumab Biosimilar Byooviz Launches in US

Biogen and Samsung Bioepis announced June 2 that Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis, has been launched in the US. It will be commercially available on July 1. The list pr...

Outlook, Xbrane to Retool BLA Submissions for Retinal Biosimilars after Request from US FDA

Outlook Therapeutics reported May 31 that it had withdrawn its biologics license application (BLA) for Lytenava, a formulation of bevacizumab for ophthalmic use, after the US FDA requested addition...

US FDA Expands Labeling for Novartis’ Beovu to Include DME

Swiss drugmaker Novartis announced June 1 that the US FDA had approved Beovu (brolucizumab-dbll) 6 mg to treat diabetic macular edema (DME). Beovu is approved to treat wet age-related macular degen...

Apellis Submits New Drug Application to US FDA for Pegcetacoplan in Geographic Atrophy

Apellis Pharmaceuticals announced June 1 that it had submitted a new drug application (NDA) to the US FDA for intravitreal pegcetacoplan, a targeted C3 therapy, for the treatment of geographic atro...

Catalyst Resells C3 Inhibitor for Dry AMD to Vertex as Investor Pressure Mounts

Catalyst Biosciences announced May 23 that it had sold its portfolio of complement drug candidates, including CB 2782-PEG for dry age-related macular degeneration (AMD), to Vertex Pharmaceuticals, ...

RetInSight Fluid Monitor Software for OCT Images Gains CE Marking

Austria’s RetInSight announced May 18 that it had obtained CE marking for its Fluid Monitor, AI-based software that analyzes and quantifies optical coherence tomography (OCT) images in patients wit...

Chugai Launches Vabysmo in Japan for Wet AMD and DME

Tokyo-based Chugai Pharmaceutical Co. reported May 25 that it had launched Vabysmo (faricimab) in Japan for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (D...

Bausch + Lomb’s Lumify Receives Health Canada Approval

Bausch + Lomb announced May 24 that its Lumify eye drops had gained Health Canada approvalto relieve redness in adult patients due to minor eye irritations. Lumify, a formulation of low-dose brimon...

Dopavision Appoints Mark S. Wuttke, PhD, as Chief Executive Officer

German company Dopavision, which is developing a light-based digital system to treat childhood myopia, announced May 25 that it had appointed Mark S. Wuttke, PhD, as chief executive officer. He suc...

Q1-2022 Ophthalmic Revenue Roundup for Iridex, Kala, Clearside

Iridex, of Mountain View, California, reported May 12 that its Q1-2022 revenue was $13.4 million, a 12 percent increase over $12 million in Q1-2021. The laser company said revenue for its Cyclo G6 ...

Oxysterol Drug Compound Shows Promise as Cataract Treatment

Researchers have successfully tested an alternative cataract treatment candidate using an oxysterol compound, VP1-001. The international team, led by scientists at UK-based Anglia Ruskin University...

ASCRS Exhibitors Reveal Plans for US Launches of Phaco Machines, Expanding Surgeon Options

US cataract surgeons have bought their ultrasonic phaco machines from three companies—Alcon, Johnson & Johnson Vision, and Bausch + Lomb—for 30 years. The number of ultrasonic machine market partic...

Alcon to Acquire Kala’s Eysuvis, Inveltys for $60 Million Up Front

Alcon announced May 23 that it would pay $60 million up front to acquire Kala’s Eysuvis for dry eye and Inveltys for post-surgical pain and inflammation. The deal includes potential sales milestone...

CorneaGen Recalls Corneal, Scleral Patch Grafts over HIV Risk

The US FDA is reporting that CorneaGen has issued urgent product recalls for certain corneal and scleral patch grafts. The corneal grafts were obtained from a donor who tested reactive for HIV-1/HI...

Ocuphire Sees Positive Topline Results from Phase III Trial of Nyxol in Night Vision Disturbances

Ocuphire Pharma announced May 19 that it saw positive topline results from the LYNX-1 Phase III pivotal trial investigating Nyxol (0.75% phentolamine ophthalmic solution) for night (or dim light) v...

Aerie Doses First Patient in Phase III Study of its TRPM8 Agonist for Dry Eye

Aerie Pharmaceuticals, maker of Rhopressa and Rocklatan for glaucoma, announced May 24 that it had dosed the first patient in the Phase III COMET-2 study of its AR-15512 ophthalmic solution in dry ...

Global PC-IOL Demand Rises Modestly, Soars in a Few Countries

Presbyopia-correcting IOLs experienced steady global growth in 2021 and record-breaking growth in a handful of countries. PC-IOLs accounted for nearly 1.65 million cataract and refractive lens exch...

Luxa Doses First Patient in Phase I/IIa Trial of Cell Product Candidate for Dry AMD

Luxa Biotechnology, a joint venture between Korea’s Y2 Solutions and the Neural Stem Cell Institute in Rensselaer, New York, announced May 24 that it had dosed the first patient in a Phase I/IIa tr...

OKYO Closes $2.5 Initial Public Offering of American Depositary Shares

OKYO Pharma, of London, announced May 19 that it had closed a $2.5 million initial public offering of 625 thousand American Depositary Shares at a price of $4 per share. The company said it would u...

Perceive Biotherapeutics Appoints Anne E. Fung, MD, as CMO

Perceive Biotherapeutics, a South San Francisco, California, company developing ophthalmic gene therapy candidates, announced May 18 that it had appointed Anne E. Fung, MD, as chief medical officer...

2022 ASCRS Meeting Prepares Ophthalmology for Future of More Efficiency, Less Waste

Some interesting new sessions at the 2022 meeting of the American Society of Cataract and Refractive Surgery (ASCRS) made it apparent that the program committees were looking to the future of ophth...

Want to Read Locked Articles?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.